Breaking News

Vertellus Completes Upgrades for API Production

May 3, 2013

Expands market capabilities to include pharmaceutical use for Niacin

Vertellus Specialties’ facility in Antwerp, Belgium has completed upgrades for the manufacture of Niacin (nicotinic acid) for pharmaceutical use. For 30 years the plant has produced Niacin USP and Niacinamide for human food applications and agricultural needs. Vertellus upgraded the facility to meet cGMP guidelines for the manufacture of an API and it has been inspected and approved by the U.S. FDA. Major changes include validation of all critical equipment, manufacturing processes, analytical methodology and data collection systems.
 
"We are very excited to broaden our market capabilities to include pharmaceutical use for Niacin," said Bentley Park, president of Vertellus Agriculture & Nutrition Specialties LLC. "Among other applications, Niacin increasingly is used as a critical ingredient in drugs that help improve cardiovascular health by increasing good cholesterol levels. We can now provide another source and more options for pharmaceutical companies making those life-saving drugs."

Related Contract Manufacturing:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks